WO2003039480A3 - Method of treating disorder related to high cholesterol concentration - Google Patents
Method of treating disorder related to high cholesterol concentration Download PDFInfo
- Publication number
- WO2003039480A3 WO2003039480A3 PCT/US2002/035900 US0235900W WO03039480A3 WO 2003039480 A3 WO2003039480 A3 WO 2003039480A3 US 0235900 W US0235900 W US 0235900W WO 03039480 A3 WO03039480 A3 WO 03039480A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- high cholesterol
- treating
- cholesterol concentration
- disorder related
- treating disorder
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000012190 activator Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002356919A AU2002356919B2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
JP2003541772A JP2005508368A (en) | 2001-11-08 | 2002-11-08 | Methods for treating diseases associated with high cholesterol levels |
EP02802882A EP1450816A4 (en) | 2001-11-08 | 2002-11-08 | METHOD FOR TREATING DISORDER IN CONNECTION WITH INCREASED CHOLESTERITE CONCENTRATION |
CA002466033A CA2466033A1 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34802001P | 2001-11-08 | 2001-11-08 | |
US60/348,020 | 2001-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003039480A2 WO2003039480A2 (en) | 2003-05-15 |
WO2003039480A3 true WO2003039480A3 (en) | 2003-06-19 |
Family
ID=23366328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/035900 WO2003039480A2 (en) | 2001-11-08 | 2002-11-08 | Method of treating disorder related to high cholesterol concentration |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1450816A4 (en) |
JP (1) | JP2005508368A (en) |
CA (1) | CA2466033A1 (en) |
TW (1) | TW200300078A (en) |
WO (1) | WO2003039480A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11851457B2 (en) | 2016-10-18 | 2023-12-26 | Sage Therapeutics | Oxysterols and methods of use thereof |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078396B2 (en) | 2001-05-03 | 2006-07-18 | Arch Development Corporation | Method of treating disorder related to high cholesterol concentration |
US8399441B2 (en) | 2004-10-25 | 2013-03-19 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis |
WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
TW200619191A (en) | 2004-10-27 | 2006-06-16 | Sankyo Co | Phenyl compounds with more than 2 substitutes |
EP2091926B1 (en) | 2006-11-13 | 2015-10-21 | Novartis AG | Substituted pyrazole and triazole compounds as ksp inhibitors |
EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X RECEPTOR AGONISTS |
US9034859B2 (en) | 2011-04-06 | 2015-05-19 | Virginia Commonwealth University | Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation |
DK2753632T3 (en) | 2011-09-08 | 2023-07-10 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF |
TR201817995T4 (en) | 2013-03-13 | 2019-02-21 | Sage Therapeutics Inc | NEUROACTIVE STEROIDS AND METHODS OF USE |
JP2016514967A (en) * | 2013-03-13 | 2016-05-26 | セージ セラピューティクス, インコーポレイテッド | Nerve stimulating steroids, compositions and uses thereof |
JP2016193835A (en) * | 2013-09-04 | 2016-11-17 | 学校法人常翔学園 | Nuclear receptor liver X receptor agonist |
ES2906865T3 (en) | 2013-12-24 | 2022-04-20 | Univ Virginia Commonwealth | Use of oxygenated cholesterol sulfates (OCS) to treat acute liver failure |
US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
PT3319611T (en) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
RS63280B1 (en) | 2016-04-01 | 2022-06-30 | Sage Therapeutics Inc | OXYSTEROLS AND PROCEDURES FOR THEIR USE |
WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
SI3481846T1 (en) | 2016-07-07 | 2021-11-30 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
US20190269695A1 (en) | 2016-08-02 | 2019-09-05 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
MA46351A (en) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS |
JP2019532079A (en) | 2016-10-18 | 2019-11-07 | セージ セラピューティクス, インコーポレイテッド | Oxysterols and methods of use |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
EP0562849A2 (en) * | 1992-03-27 | 1993-09-29 | Eli Lilly And Company | Steroid derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4976857A (en) * | 1972-12-06 | 1974-07-24 | ||
US4217288A (en) * | 1977-03-24 | 1980-08-12 | Wisconsin Alumni Research Foundation | Anti-vitamin D compounds |
JPS61254599A (en) * | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | Fluorine derivative of cholesterol |
IT1255241B (en) * | 1992-07-22 | 1995-10-20 | Simos Contos | BILIARY ACID DERIVATIVE AND ITS USE IN THERAPY |
AU775630B2 (en) * | 1999-04-30 | 2004-08-05 | Arch Development Corporation | Steroid derivatives |
JP4309661B2 (en) * | 2001-05-03 | 2009-08-05 | ザ ユニバーシティー オブ シカゴ | Liver X receptor |
-
2002
- 2002-11-08 JP JP2003541772A patent/JP2005508368A/en active Pending
- 2002-11-08 EP EP02802882A patent/EP1450816A4/en not_active Withdrawn
- 2002-11-08 CA CA002466033A patent/CA2466033A1/en not_active Abandoned
- 2002-11-08 TW TW091132850A patent/TW200300078A/en unknown
- 2002-11-08 WO PCT/US2002/035900 patent/WO2003039480A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3963765A (en) * | 1973-04-01 | 1976-06-15 | Yehuda Mazur | Preparation of derivatives of cholesterol |
EP0562849A2 (en) * | 1992-03-27 | 1993-09-29 | Eli Lilly And Company | Steroid derivatives |
Non-Patent Citations (3)
Title |
---|
ARCH. BIOCHEM. BIOPHYS., vol. 98, 1962, pages 305 - 311 * |
DATABASE CAPLUS [online] WHITEHOUSE M. ET AL.: "Catabolism in vitro of cholesterol: some comparative aspects", XP002963337, accession no. STN Database accession no. 1962:464382 * |
See also references of EP1450816A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11851457B2 (en) | 2016-10-18 | 2023-12-26 | Sage Therapeutics | Oxysterols and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1450816A4 (en) | 2008-02-13 |
TW200300078A (en) | 2003-05-16 |
EP1450816A2 (en) | 2004-09-01 |
JP2005508368A (en) | 2005-03-31 |
CA2466033A1 (en) | 2003-05-15 |
WO2003039480A2 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003039480A3 (en) | Method of treating disorder related to high cholesterol concentration | |
BR0114576A (en) | Compound, pharmaceutical composition, use of a compound, method of treating a disease state and process for preparing a compound | |
DE69512797D1 (en) | Prostaglandin-synthase hemmer | |
BR0316375A (en) | Diazinopyrimidines | |
WO2001052796A3 (en) | Methods of using a beverage composition for treating dental erosion | |
ATE410400T1 (en) | METHOD FOR PRODUCING C13 ALCOHOL MIXTURES | |
MXPA03011681A (en) | Methods of using soluble epoxide hydrolase inhibitors. | |
BR0310106A (en) | Compound, process for producing a compound, pharmaceutical composition, use of the compound and method for treating a subject suffering from a pathological condition or disease | |
DE60024830D1 (en) | METHOD FOR PRODUCING HETEROARYL SUBSTITUTED UREA BONDING | |
MXPA03009840A (en) | Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments. | |
HK1085675A1 (en) | Anticancer compounds | |
EA199800620A1 (en) | SUBSTITUTED N - [(AMINOIMINOMETHYL OR AMINOMETHYL) PHENYL] PROPYLAMIDE | |
WO2005030120A3 (en) | Antiangiogenic agents | |
WO2003024391A3 (en) | Treatment and prevention of mucositis in cancer patients | |
WO2003009803A3 (en) | Method of improving cognitive function | |
ATE430572T1 (en) | USE OF SPONGOSIN (2-METHOXYADENOSINE) FOR THE TREATMENT OF PAIN, ESPECIALLY HYPERALGESIA | |
AU1185801A (en) | Novel compounds | |
WO2003022280A3 (en) | 3-glyoxlylamideindoles for treating cancer | |
DE60202203D1 (en) | NEW METHOD FOR THE PRODUCTION OF OXABISPIDINES | |
EA200600100A1 (en) | DERIVATIVES NICOTINAMIDA USEFUL AS PDE4 INHIBITORS | |
BR0312470A (en) | Compound, use thereof, pharmaceutical composition, method of treating and / or preventing cancer, and process for preparing the compound | |
DE602004009664D1 (en) | Diclazuril-containing antiperspirants | |
BR0308601A (en) | plasma carboxypeptidase b inhibitors | |
NO993806L (en) | Process for the preparation of iodinated contrast agents and intermediates for these | |
MXPA05013901A (en) | Use of alpha-ketoglutaric acid for the treatment of malnutrition or high plasma glucose condition. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2466033 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003541772 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002356919 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002802882 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002802882 Country of ref document: EP |